KRAS and neoplasm: We also observed less viable tumor cells after Ipi+Nivo+CT in tumors harboring KRAS and TP53 alterations, consistent with prior results demonstrating improved outcomes to immunotherapy in these molecular subgroups20–24, similar to the exploratory analyses of the CheckMate-227 part 1 study, which revealed improved OS in patients with KRAS-mutant and TP53-mutant metastatic tumors treated with Ipi+Nivo compared with CT25.